fda bpc-157 status regulation 503A Decision: Why It Wasn't Added to the… In a major policy shift, – bpc-157 regulatory status fda warning

Moreover, a comparison of the number of animals with unhealed defects (all controls) or healed defects (complete bony continuity across the defect site) showed that besides pentadecapeptide intramuscular application for 14 days (i.e., local application of bone marrow or autologous cortical graft), also following other pentadecapeptide BPC-157 regimens (local application, or intermittent intramuscular administration), the number of animals with healed defect was increased

After a month or so, you may begin seeing lower numbers on the scale

Comparison to BPC-157 : Not in the same league

Oral supplements work as a slow climb